{
  "id": "mhgap#risk_safety_96fc4611",
  "content": "only be prescribed under mental health specialist y Treatment with antipsychotic medicines or mood\nsupervision. If laboratory examinations are not stabilizers should be combined with psychosocial\navailable or feasible, lithium should be avoided and interventions (see other recommendations in\nother mood stabilizers or antipsychotics should this module).\nbe considered. Do not prescribe lithium where the y Acquisition costs can differ substantially and also\nlithium supply may be frequently interrupted due to throughout the world. Recent antipsychotics may\nincreased risk of relapse. Clinicians should conduct have higher costs than older antipsychotics.\nkidney and thyroid function, complete blood count, y Discontinuities in medicine availability (common\nelectrocardiogram (ECG) and pregnancy tests before in LMICs) may interfere with the continuation\nbeginning treatment where possible. of treatment.\ny Sodium valproate should not be used in women y Lithium carbonate, carbamazepine and quetiapine\nand girls of childbearing potential because of the (therapeutic alternatives: aripiprazole, olanzapine,\nhigh risk of birth defects and neurodevelopmental paliperidone) are available in the WHO EML (13).\ndisorders in children exposed to sodium valproate in\nutero (see recommendation PSY8.2).\n91\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders\nPSY4. In adults with psychotic disorders (including schizophrenia)",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "study",
      "risk_safety",
      "referral",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General â€” Risk Safety only be prescribed under mental health specialist y Treatment with antipsychotic medicines or mood\nsupervision. If laboratory examinations are not stabilizers should be combined with psychosocial\navailable or feasible, lithium should be avoided and interventions (see other recommendations in\nother mood stabilizers or antipsychotics should this module).\nbe considered. Do not prescribe lithium where the y Acquisition costs can differ substantially and also\nlithium supply may be frequently interrupted due to throughout the world. Recent antipsychotics may\nincreased risk of relapse. Clinicians should conduct have higher costs than older antipsychotics.\nkidney and thyroid function, complete blood count, y Discontinuities in medicine availability (common\nelectrocardiogram (ECG) and pregnancy tests before in LMICs) may interfere with the continuation\nbeginning treatment where possible. of treatment.\ny Sodium valproate should not be used in women y Lithium carbonate, carbamazepine and quetiapine\nand girls of childbearing potential because of the (therapeutic alternatives: aripiprazole, olanzapine,\nhigh risk of birth defects and neurodevelopmental paliperidone) are available in the WHO EML (13).\ndisorders in children exposed to sodium valproate in\nutero (see recommendation PSY8.2).\n91\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders\nPSY4. In adults with psychotic disorders (including schizophrenia) Only be prescribed under mental health specialist y treatment with antipsychotic medicines or mood\nsupervision. if laboratory examinations are not stabilizers should be combined with psychosocial\navailable or feasible, l..."
}